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Abstract
In patients with Late-Onset Pompe Disease (LOPD), progressive respiratory muscle involvement leads to reduced pulmonary function, with
respiratory failure the most common cause of mortality. Early disease manifestations include sleep-disordered breathing, which can be treated with
non-invasive ventilation; however, progressive diurnal deficits can require invasive ventilation. To determine if pulmonary function tests (PFTs)
predict the thresholds for ventilation and wheelchair use, a systematic literature review identified cross-sectional clinical patient data (N = 174) that
was classified into ventilation and wheelchair cohorts. PFTs included maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP),
forced vital capacity (FVC), and vital capacity (VC), with vital capacities measured in the upright (-U) and supine (-S) positions. Receiver
operating characteristic (ROC) curves were used to calculate cut-points (CP) and area under the curve (AUC). For all ventilation and mobility
thresholds tested, ROC analyses demonstrated AUC values from 86–89% for MIP, 72–96% for MEP, and 74–96% for all vital capacity metrics.
Thus, PFTs are useful in predicting the thresholds for nighttime ventilation, daytime ventilation, and wheelchair use, with MIP and VC-U having
both high AUC values and consistency. The PFT mobility CPs were low (MIP CP = 0.9 kPa, MEP, CP = 2.6 kPa, VC-U CP = 19% predicted),
suggesting an endurance component associated with wheelchair use.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Late-Onset Pompe Disease (glycogen storage disorder type 2,
acid maltase deficiency, LOPD) is a rare genetic disorder
characterized by attenuated functionality of the enzyme acid alpha-
glucosidase. The resulting accumulation of glycogen in skeletal
and respiratory muscles can result in myopathy, with progressive
deterioration in both mobility and pulmonary function. As a
heterogeneous disorder, clinical disease can present throughout
life, from young childhood (>2 years) through adulthood. In over
70% of LOPD patients, respiratory failure is the most common
cause of mortality [1,2]. Longitudinal quality of life surveys have
demonstrated reductions in the physical health domains in a
step-wise manner with the addition of respiratory support
(nighttime and daytime ventilators) and mobility assistance
devices (e.g. wheelchairs) [3–5].
With progressive decline of critical respiratory muscle function
(e.g. diaphragm), sleep disordered breathing may arise with
associated symptoms of morning headache, daytime somnolence
and fatigue [6,7]. Studies on sleep in patients with neuromuscular
disorders (congenital muscular dystrophy, Duchenne muscular
dystrophy, spinal muscular atrophy type I-II, limb-girdle
dystrophy, late-onset Pompe disease/acid maltase deficiency,
nemalinemyopathy, hereditarymotor and sensory neuropathy type
I, centronuclear myopathy, myotonic dystrophy, and non-classified
myopathy) have suggested that the onset of both sleep-disordered
breathing (SDB) and nocturnal hypoventilation (NHV) can be
predicted with daytime pulmonary function measurements (e.g.
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inspiratory vital capacity, IVC; maximum inspiratory pressure,
MIP) [8–11]. In neuromuscular disorders, the introduction of
nighttime ventilation has been shown to significantly improve the
restfulness of sleep (daytime sleepiness; morning headache) and
correct daytime hypoxemia and hypercapnia [12,13].
In addition to sleep studies, pulmonary function tests (PFT),
specifically MIP and FVC, have been used to establish the need
and financial reimbursement for nocturnal mechanical ventilation
in patients with neuromuscular disorders [14,15].While the health
insurance systems in the United States and the United Kingdom
have defined PFT criterion for reimbursement of nocturnal
ventilation [15,16], these have not been adopted internationally
and there are no proposed criteria for daytime ventilation. Since
the implementation of nocturnal, and subsequently, daytime
ventilation are important milestones in the progression of LOPD,
the present study was designed to evaluate if non-invasive
pulmonary function tests (PFTs) can be used to describe the
predictive thresholds for both nocturnal and diurnal ventilator
usage. In addition, as respiratory function can affect endurance and
mobility, this study also examined the ability of PFTs to describe
the predictive threshold between a mobile state and wheelchair
usage.
2. Methods
2.1. Search strategy
Clinical studies reporting both pulmonary function metrics and
ventilator use of individual LOPD patients were identified using
electronic searches of both EMBASE and MEDLINE database
on October 7, 2014. The search terms included the following
terms: (“pompe” OR “glycogen storage disease type 2” OR “acid
maltase” OR “glycogenosis”)AND (“respiratory” OR “ventilator”
OR “pulmonary”). Using the SCOPUS database, additional
studies were identified from subsequent articles that had cited
the initial list of clinical studies that had passed the screening
process.
To identify only individuals with late-onset disease, clinical
studies and case reports of patients ≥2 years with both pulmonary
function test (PFT) results and a description of ventilator usage
were included. Exclusion criteria also comprised studies
reporting on animal models, infantile Pompe disease (<2 years),
other diseases, disease management guidelines, diagnostic tools,
genotype-phenotype studies, and articles written in languages
other than English. The selection criteria, shown in Fig. 1,
identified 34 studies with patient level data reporting at least 1
PFT and a description of ventilator status [6,17–49].
2.2. Data identification and analyses
Individual data were identified from the included clinical
studies. Averaged values were not used. Pulmonary function data
included two measures of respiratory muscle strength, maximum
inspiratory pressure (MIP), and maximum expiratory pressure
(MEP), as well as four measures of lung volume, vital capacity in
the upright (VC-U) and supine (VC-S) positions, forced vital
capacity in the upright (FVC-U) and supine (FVC-S) positions.
Fig. 1. Systematic literature review to identify clinical data for pulmonary function tests and ventilator status for patients with late-onset Pompe disease.
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The respiratory muscle strength measurements (MIP, MEP) were
analyzed in terms of pressure (kPa), while the lung capacity
metrics (VC, FVC) were analyzed as percent of predicted values
(% predicted). The respiratory muscle strength measurements are
typically reported as absolute values and not normalized for age
or gender. These metrics were the most commonly reported tests
in the literature, providing sufficient data for these analyses. Data
were excluded if descriptions of ventilator status for individual
patients were inadequate. Clinical data from patients who were
treated and untreated with enzyme replacement therapy (ERT)
were included, with the assumption that treatment may alter the
trajectory of progression but not the relationship between each
PFT parameter and ventilator/ambulation status. To assess the
degree to which treatment (or lack thereof) may influence these
analyses, a statistical comparison of the treated vs. non-treated
patients within each cohort was also performed.
Ventilator status was determined by either a written
description in the study (no ventilation, nighttime ventilation,
or daytime ventilatory assistance) or a description of the
ventilator time usage per day (with ≤ 12 hours representing
nocturnal ventilation and > 12 hours representing daytime use).
Preference between these two methods was given to the written
description in the text. To incorporate the possible addition of
ventilation during longitudinal progression, up to 4 data points
per individual were included, with a minimum of 3 months
between measurements.
To determine the ability of PFTs to predict the thresholds in
ventilator status, clinical data were assigned to 1 of 3 cohorts, as
defined with no ventilation (none), nighttime ventilation (night),
or daytime ventilation (day). These cohorts were analyzed using
receiver operating characteristic (ROC) curves, determining the
cut point (CP, from the maximum likelihood ratio), the area under
the curve (AUC), as well as the sensitivity and specificity values.
Analyses were performed with GraphPad Prism version 6.05
(GraphPad Software, La Jolla, CA, USA). Each PFT was
considered separately, evaluating the hypothesis that each metric
could independently predict these threshold points. AUC values
of 100% represent a perfect differentiation between the groups.
In addition, an analysis using only a single point from each
patient was also performed to determine if there was an inherent
bias with the inclusion of longitudinal data.AsVC and FVC have
been used interchangeably in the literature, additional analyses
were performed using combined data sets for VC-U and FVC-U,
as well asVC-S and FVC-S. For individual patient data reporting
both a VC and an FVC metric, the larger value was used in the
combined analyses.
To determine the ability of PFTs to differentiate ambulation
and wheelchair use, well-characterized clinical data were
assigned to 1 of 2 cohorts (mobile or wheelchair) and also
analyzed using ROCs.Wheelchair status was defined by a written
description of wheelchair usage, a description stating that a six-
minute walk test (6MWT) was not feasible, or a Walton
score ≥ 7. Mobile status was defined by a written description of
mobility, a value for the 6MWT, or aWalton score < 7. Individual
patient data with inadequately characterized descriptions of
mobility were classified as unknown and not used for this
mobility analysis.
3. Results
3.1. Patient characteristics
From the 34 included studies, clinical data describing
ventilator status and at least one PFT were identified for 174
individual patients (N), with characteristics shown in Table 1.
With the inclusion of up to 4 data points per individual patient
with at least a 3-month separation between observations, a total
number of observations (n) of 267 were identified and used
in these analyses. The ages of the patients at the time of
observation are also shown in this table, as well as the countries
that the studies originated in. As these reported data had been
de-identified, there was the possibility that individual patient
data may have been represented in multiple reports. To
determine if there were duplicate records, patient data in
different studies from the same authors and/or within the same
country were compared using gender and age. Using this
method, there were no individual data that overlapped. To
evaluate a possible effect that treatment may have on these
analyses, the clinical data points were also characterized as
untreated or treated with ERT. Within each PFT (MIP, MEP,
VC-U, FVC-U), data were grouped according to treatment and
analyzed with a student t-test to determine if there were
statistically relevant differences that may affect the ROC
analyses. For the observational data, 164 data points were
obtained for untreated and 78 data points were identified as
ERT treated. The remaining undefined data were not used in
this analysis. In comparing the treated vs. untreated data, the
p-values from the student t-test for the three ventilation cohorts
(none; night; day) were calculated for MIP (0.55; 0.96; 0.23),
Table 1
Patient characteristics.
Individual patients (N) Total observations (n)
174 267
Gender
Male 70
Female 78
None specified 26
Age at observation
2–17 years 34
18–39 years 61
40–59 years 121
≥60 years 42
None specified 9
Country of clinical study
Canada 3
France 54
Germany 19
Hungary 7
Italy/Belgium 35
Japan 9
Netherlands 31
Switzerland 7
United Kingdom 3
United States 6
N: the number of individual LOPD patients. n: the number of observations used
in the analysis (maximum of 4 points per individual, with a minimum of 3
months between measurements).
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MEP (not feasible; 0.08; 0.46), VC-U (0.30; 0.35; 0.24),
FVC-U (0.78; 0.57; 0.47), VC-S (0.19; 0.23; 0.13), FVC-S (not
feasible; 0.48; not feasible), respectively. These p-values all
exceed 0.05, suggesting that within each cohort there were no
statistical differences between the untreated and treated data.
3.2. Predictive thresholds for ventilator use
As shown in Table 2, non-invasive PFTs were able to describe
the two predictive thresholds for ventilator use with high AUC
values.The number of observations (n) used for each parameter are
also provided in this table. A visual representation of the data
points and ROC curves for the 6 parameters (MIP, MEP, VC-U,
VC-S, FVC-U, FVC-S) are shown in Fig. 2.
3.2.1. Threshold for nighttime ventilation
In differentiating the no ventilation and nighttime ventilation
groups, 5 metrics (MIP, FVC-U, VC-U, FVC-S, VC-S) were
able to predict these thresholds with AUC values ≥83%. For the
two respiratory muscle strength metrics (MIP, MEP), only MIP
was able to describe the predictive threshold between the no
ventilation and nighttime ventilation groups with high
differentiation (CP = 2.8 kPa, AUC = 89%, p < 0.0001). For
MEP, there was considerable overlap between the no ventilation
and the nighttime ventilation groups, as characterized by a
moderate AUC value (CP = 3.0 kPa, AUC = 72%, p = 0.03).
In examining the lung capacity tests, the cut points for VC-U
(45% predicted) and FVC-U (39% predicted) for the thresholds
between the no ventilation and nighttime ventilation groups had
similar values. In the combined analysis of FVC-U and VC-U,
the cut point (40% predicted) was between the values determined
for the 2 individual metrics. For the supine vital capacity
measurements, VC-S (CP = 25% predicted) provided good
differentiation between the no ventilator and nighttime ventilator
groups. Unexpectedly, a lower AUC value was noted for FVC-S
which may reflect the relative lack of data reported for this
parameter. Supine measurements can be difficult to obtain in
LOPD, as this position can result in severe dyspnea and may be
intolerable. Consistent with the reported diaphragmatic weakness
in this disorder, the cut points for vital capacity in the supine
position were lower than the corresponding values determined in
the upright position.
3.2.2. Threshold for daytime ventilation
In determining the predictive thresholds between the nighttime
ventilation and daytime ventilation groups, five parameters (MIP,
MEP, FVC-U, VC-U, VC-S) were, to varying degrees, able to
differentiate these two states with AUC values ≥80%, as shown in
Table 2. There were not enough data points to evaluate the
predictive threshold for FVC-S.The predictive thresholds between
the nighttime and daytime cohorts for these parameters were all
distinctly lower than the values determined for the thresholds
between no ventilation and nighttime ventilation, indicating that
lung function decreased with disease progression.
For the respiratory muscle strength metrics, MIP described
both ventilation thresholds with the sameAUC values (89%). For
MEP, the ability to differentiate the two ventilator predicative
thresholds was distinctly different, as shown in Table 2.
With the exception of FVC-S (there were too few data points
for this analysis), the lung capacity tests were able to predict the
threshold points between nighttime ventilation and daytime
ventilatory assistance groups. Unexpectedly, the AUC values for
FVC-U were lower for the threshold for daytime assistance
(80%) than the nighttime value (87%). This decrease was not
observed with theVC-U values alone. However, in the combined
analysis with both FVC-U and VC-U, the AUC values were
different for the thresholds between the no ventilation and
nighttime groups (92%) and the nighttime and daytime
ventilation groups (84%).
Table 2
Prediction of nighttime and daytime ventilator use by non-invasive pulmonary function tests in LOPD.
Threshold for nighttime ventilator Threshold for daytime ventilator
Parameter None (n) Night (n) Cut point Sensitivity/specificity (%) AUC (%) Day (n) Cut point Sensitivity/specificity (%) AUC (%)
MIP (kPa) 37 43 2.8 63/95 89%
p < 0.0001
21 1.1 57/98 89%
p < 0.0001
MEP (kPa) 20 15 3.0 47/95 72%
p = 0.03
18 2.4 89/80 95%
p < 0.0001
FVC-U (% predicted) 47 37 39 35/98 87%
p < 0.0001
28 17 32/97 80%
p < 0.0001
VC-U (% predicted) 57 49 45 63/98 96%
p < 0.0001
25 19 88/98 96%
p < 0.0001
FVC-S (% predicted) 14 8 32 75/93 83%
p = 0.01
– – – –
VC-S (% predicted) 23 19 25 58/96 96%
p < 0.0001
14 12 71/95 86%
p < 0.0004
VC-U & FVC-U
(% predicted)
104 80 40 48/99 92%
p < 0.0001
45 19 51/99 84%
p < 0.0001
VC-S & FVC-S
(% predicted)
36 27 33 81/94 94%
p < 0.0001
14 12 71/89 89%
p < 0.0001
Dash (–) indicates that there were not enough data points reported to perform this analysis. n: the number of observations assigned to each cohort. Cut point: value
with the highest likelihood ratio from the ROC analysis. U: measurements performed in the upright position. S: measurements performed in the supine position.AUC
(%): values of 100% represent a perfect discrimination between the 2 groups. None: group with no ventilation. Night: group with nighttime ventilation. Day: group
with daytime ventilation.
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Fig. 2. (A–F) Data points and receiver operating characteristic (ROC) curves for the 2 ventilator thresholds, no ventilation (none) – nighttime ventilation (night)
groups and nighttime ventilation – daytime ventilation (day) groups. Mean (±SD) values are shown for each cohort as a line with error bars. (A) MIP (maximum
inspiratory pressure, kPa). (B) MEP (maximum expiratory pressure, kPa). (C) FVC-U (forced vital capacity in the upright position, % predicted). (D) VC-U (vital
capacity in the upright position, % predicted). (E) FVC-S (forced vital capacity in the supine position, % predicted). There were insufficient data points for patients
with daytime ventilation to complete the ROC analysis for the nighttime and daytime ventilation groups for FVC-S. (F) VC-S (vital capacity in the supine position,
% predicted).
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To determine if there was a bias with the inclusion of
longitudinal data, an ROC analysis using only one data point
from each included patient was also performed. For individuals
with multiple values, the lowest value was used in this
additional analysis. For the two ventilator analyses (none and
night groups; night and day groups), the single data point
analysis produced values for MIP (CP = 2.5 kPa, AUC = 89%;
CP = 1.2 kPa, AUC = 90%), MEP (CP = 3.0 kPa, AUC = 67%;
CP = 2.5 kPa, AUC = 92%), FVC-U (CP = 39% predicted,
AUC = 86%; CP = 20% predicted, AUC = 80%), VC-U
(CP = 45% predicted, AUC = 96%; CP = 18% predicted,
AUC = 96%), FVC-S (CP = 31% predicted, AUC = 88%; no
available data for daytime analysis), and VC-S (CP = 25%
predicted, AUC = 96%; CP = 11% predicted, AUC = 89%),
respectively. The similarities between these values and the
calculated values using the entire data set, as reported in
Table 2, suggest that there was minimal/no bias with the
inclusion of longitudinal data.
3.3. Predictive threshold for wheelchair use
To determine if measures of lung function could be used to
predict the threshold between the mobile and wheelchair
groups, the identified data were grouped into 2 cohorts (mobile;
wheelchair) and analyzed with ROC curves. As shown in
Table 3, the pulmonary function parameters were able to
differentiate these two groups. Data points and ROC curves for
these analyses are also shown in Fig. 3A–F.
Among the PFTs, the respiratory muscle strength metrics
(MIP, MEP) had the highest AUC values of 86% and 95%,
respectively. With the exception of FVC-S (not enough data
points in the wheelchair cohort for an analysis), the lung
capacity metrics were also able to predict these thresholds. In
contrast with the ventilation analyses, the predictive thresholds
for the vital capacity measurements for the upright and supine
positions were not distinctly different. In addition, the cut point
values were also quite low and well below the values observed
for the predictive threshold values determined for the no
ventilation to nighttime ventilatory support groups, supporting
a discordance between progression of respiratory muscle vs.
peripheral skeletal muscle weakness.
4. Discussion
The addition of ventilator assistance and wheelchair use are
significant events in the progression of LOPD. In a study on the
quality of life of 210 LOPD patients, the addition of ventilation
and/or wheelchair use was associated with a maximal negative
impact in the physical functioning scores on the SF-36 survey,
with the these events ranked in the following order: ventilator
and wheelchair use > > ventilator only > wheelchair only [3].
For these important events, clinically relevant surrogate tests to
appropriately monitor disease progression would be beneficial.
The tight associations observed between pulmonary function
metrics and ventilator/wheelchair use suggest that lung function
parameters may be useful in monitoring the possible onset of
these events.
Prior studies in patients with primary myopathies have
evaluated the relationship between respiratory function and
presence of sleep disordered breathing and diurnal respiratory
failure. These studies demonstrated that as respiratory dysfunction
progresses patients develop sleep disordered breathing which
progresses to nocturnal hypoventilation, manifest as hypercapnia
during sleep, and eventually development of diurnal respiratory
failure. The cut points identified in these prior studies for the
presence of nocturnal hypoventilation and diurnal respiratory
failure coincides with the cut points identified in the present study
for the nighttime and daytime ventilation groups, respectively. Of
importance, these studies demonstrated that the onset of sleep
disordered breathing occurs at rather high levels of respiratory
function (vital capacity < 60% predicted, MIP < 4.5 kPa),
indicating that the onset of sleep disordered breathing can be easily
missed without direct assessment of respiration and/or gas
exchange during sleep. The present study extends these
observations to a diverse group of patients with LOPD frommany
countries and by identification of thresholds for supine vital
capacity to account for the diaphragmatic weakness that is
characteristic of LOPD.
In the present study, data for vital capacity were collected
from published studies that used differing measurement
techniques (e.g. FVC, slow VC, IVC). Whereas the measured
vital capacity will not vary by the respiratory maneuver in
healthy subjects, lower values for FVC can be observed in
patients with airway obstruction (e.g. asthma) [50]. In our
study, separate analyses were performed for FVC vs. VC.
Although differences for the cut points were observed, they
were minimal and likely reflect variability in the underlying
populations used in these studies. Since, to the best of our
knowledge, there are no reports suggesting that respiratory
Table 3
Prediction of wheelchair use by non-invasive pulmonary function tests in
LOPD.
Parameter Threshold between mobile and wheelchair groups
Mobile
(n)
Wheelchair
(n)
Cut
point
Sensitivity/
specificity
(%)
AUC (%)
MIP (kPa) 62 28 0.9 39/98 86%
p < 0.0001
MEP (kPa) 28 22 2.6 90/96 95%
p < 0.0001
FVC-U
(% predicted)
81 22 13 23/99 84%
p < 0.0001
VC-U
(% predicted)
64 38 19 58/98 82%
p < 0.0001
FVC-S
(% predicted)
– – – – –
VC-S
(% predicted)
13 17 12 59/92 74%
p = 0.03
VC-U & FVC-U
(% predicted)
142 49 13 22/93 83%
p < 0.0001
VC-S & FVC-S
(% predicted)
34 18 12 56/97 84%
p < 0.0001
Dash (–) indicates that there were not enough data points reported to perform
this analysis. n: the number of observations assigned to each cohort. Cut point:
value with the highest likelihood ratio from the ROC analysis. U: measurements
performed in the upright position. S: measurements performed in the supine
position. AUC (%): values of 100% represent a perfect discrimination between
the 2 groups.
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dysfunction in LOPD is characterized by airway obstruction,
the combined analysis which includes data from all studies may
provide the most accurate assessment of the cut points.
Pulmonary function test criterion, in particular MIP and FVC,
have been used as requirements for funding the equipment for
non-invasive ventilation. In the United States, the Centers for
Medicare and Medicaid (CMS) requirements for funding
ventilation assistance can be satisfied for neuromuscular disorders
with a criterion of either FVC < 50% predicted or MIP < 60
cmH2O (5.9 kPa) [15].These criteria were reportedly derived from
studies in patients with amyotrophic lateral sclerosis (ALS)
[51,52]. Even with these recommendations, Mendoza et al. (2007)
found that patients with ALS reached the MIP criterion 4–6.5
months earlier than the FVC criterion [52].While our study did not
have sufficient data for a longitudinal analysis, our data for LOPD
patients did suggest that nocturnal and daytime mechanical
ventilator support was more tightly linked to MIP values less than
60 cmH2O (5.9 kPa) than to values of FVC or VC in the upright
position below 50% predicted. Analysis of individual patient
values revealed that 31% (17/55) of the LOPD patients using
nighttime ventilation had vital capacity measurements exceeding
50% predicted, indicating that a large population of patients would
not qualify for ventilation reimbursement using either the CMS
or NICE criteria in the absence of additional measurement of
respiratory muscle strength. In contrast, only 8% (3/37) of the
LOPD patients with nighttime ventilation had MIP values
exceeding 60 cmH2O (5.9 kPa). Even for the more stringent NICE
criterion of MIP < 40 cmH2O (3.9 kPa), only 16% (6/37) of
the LOPD patients did not meet these requirements. In
addition, although all patients treated with nocturnal ventilation
Fig. 3. (A–F) Data points and receiver operating characteristic (ROC) curves for the thresholds between the mobile and wheelchair groups. (A) MIP (maximum
inspiratory pressure, kPa). Mean (±SD) values are shown for each cohort as a line with error bars. (B) MEP (maximum expiratory pressure, kPa). (C) FVC-U (forced
vital capacity in the upright position, % predicted). (D) VC-U (vital capacity in the upright position, % predicted). (E) FVC-S (forced vital capacity in the supine
position, % predicted). (F) VC-S (vital capacity in the supine position, % predicted).
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demonstrated values for VC or FVC in the supine position below
50% predicted, it is unclear if these supine measurements
would satisfy either the CMS or NICE guidelines, especially if
simultaneous upright values were above this threshold. With these
guidelines for ventilation reimbursement, these data demonstrate
that many subjects will achieve the MIP criteria before the VC
criteria.
The predictive threshold for VC for nighttime ventilation was
similar to the criteria that justifies reimbursement by CMS,
suggesting a potential bias. However, this study included patients
from multiple countries, and reimbursement thresholds were
only in place for the US and recently (since 2010) for the UK
(National Institute for Health and Care Excellence, NICE). There
were only a total of 9 individuals in this study who were from
either the US or the UK, as shown in Table 1. While not
excluding the possibility that physicians in the other countries
could have used the CMS/NICE guidelines, reimbursement of
NIV therapy in the majority of patients included in our study
would not have been contingent on the measured lung function.
Moreover, approximately 1/3 of the patients receiving nocturnal
ventilation had measured values of vital capacity exceeding 50%
predicted, indicating that other criteria for initiating therapy had
clearly been used. It is also unlikely that MIP criteria were used
in all of these subjects, as this parameter was monitored less
frequently in the patients included in our study. Although the
retrospective nature of our study does not allow definitive
determination of the indication for nocturnal ventilation in
individual patients, the thresholds that we determined were
highly reproducible despite variable locations/countries and
prescribing physicians. Lastly, the thresholds we identified for
nocturnal ventilation are physiologically plausible, as these
values coincide with the level of respiratory function where
hypoventilation first manifests during sleep in patients with
respiratory muscle weakness, as discussed previously.
As a heterogeneous disorder, the progressive muscle
involvement in LOPD can vary substantially with diverse
requirements for mobility and respiratory assistive devices
[53]. While wheelchair assistance is generally thought to be
related to decreased function of the motor muscles, there may
be a respiratory or endurance component that contributes to
the decision to use a wheelchair. Case study observations have
suggested that respiratory distress or exertional dyspnea may
be factors in wheelchair use [21,22]. Our analysis does indicate
that PFTs (MIP, MEP, FVC-U, VC-U, VC-S) can be used to
distinguish mobility from wheelchair use. In particular, our
analysis suggested that the threshold for wheelchair use coincided
with the need for daytime ventilation assistance. Although
speculative in nature, the use of predictive thresholds for
wheelchair use is a novel finding, which warrants additional
investigation. We cannot exclude, for example, a direct influence
of the seated position and/or scoliosis in the evolution of
respiratory status (e.g. the lack of exercise may, by itself,
decrease pulmonary function). In addition, the equipment
requirements for daytime ventilation may influence the use of
a wheelchair for mobility. Prospective, longitudinal studies to
evaluate the multiple factors that may influence wheelchair use
would be needed to fully characterize this mobility transition.
Our study may be limited by the heterogeneity of the
reported data. Different methodologies for determining the PFTs
may contribute to variability in these analyses. In addition, as a
cross-sectional study, the individual requirements for initiating
ventilation and wheelchair use cannot be discerned. Longitudinal
studies monitoring PFTs, SDB, nocturnal hypoventilation, and
diurnal respiratory failure, as well as ventilation and wheelchair
events, would be beneficial. Previous studies have also shown a
strong association between pulmonary function and scoliosis in
LOPD patients [54]. In a Pompe registry, scoliosis was reported
in the majority (62.5%) of wheelchair users for all age groups.
Also, a larger percentage of patients with scoliosis required
respiratory support than patients without scoliosis (44% vs.
27.2%, respectively). In the included studies, data describing the
presence and degree of scoliosis were uncommon, precluding an
assessment of the impact of scoliosis on the entire study. It should
be noted, however, that scoliosis may contribute to both the
observed reduced pulmonary function and wheelchair use.
5. Conclusion
In LOPD, the addition of ventilation and/or wheelchair use are
significant events in disease progression, negatively affecting
quality of life. Our findings suggest that measures of pulmonary
function (MIP, MEP, FVC, VC) can act as surrogate markers to
predict the thresholds for ventilation (nighttime; daytime). MIP
and VC in the upright position had high AUC values and
consistency in predicting these thresholds. In comparison to sleep
studies reported in the literature, the threshold points for nighttime
ventilation coincided with values that are associated with presence
of nocturnal hypoventilation in primary myopathies. In an
exploratory analysis on a possible relationship between respiratory
function and mobility, pulmonary function tests were also
associated with wheelchair use. Pulmonary function tests may aid
in identifying patients at risk for ventilation andmonitoring disease
progression in patients with late-onset Pompe disease.
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